Oculis Holding AG (OCS)

NASDAQ: OCS · Real-Time Price · USD

12.17

0.00 (0.00%)

At close: Sep 4, 2026, 4:00 PM EDT

12.12

-0.05 (-0.44%)

After-hours: Sep 4, 2026, 7:30 PM EDT

Oculis Holding AG Employees

Oculis Holding AG had 60 employees as of December 31, 2025. The number of employees increased by 11 or 22.45% compared to the previous year.

Employees

60

Change (1Y)

11

Growth (1Y)

22.45%

Revenue / Employee

$24,196

Profits / Employee

-$1,633,457

Market Cap

751.28M

Employees Chart

Employees History

Date	Employees	Change (1Y)	Growth (1Y)
Dec 31, 2025	60	11	22.45%
Dec 31, 2024	49	13	36.11%
Dec 31, 2023	36	8	28.57%
Dec 31, 2022	28	-	-
Sep 30, 2022	32	-	-
Jun 30, 2022	32	-	-

Related Stocks

Company Name	Employees
Gyre Therapeutics	625
Phathom Pharmaceuticals	371
MapLight Therapeutics	133
Neurogene	131
Aura Biosciences	113
Verastem	102
BridgeBio Oncology Therapeutics	88
Assembly Biosciences	73

Employee Rankings

OCS News

14 days ago - First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis - GlobeNewsWire
24 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
4 weeks ago - Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company - GlobeNewsWire
4 weeks ago - Oculis Reports Q2 2026 Financial Results and Provides Company Update - GlobeNewsWire
4 weeks ago - Oculis Holding AG Earnings release: Q2 2026 - Filings
5 weeks ago - Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses - GlobeNewsWire
2 months ago - Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference - GlobeNewsWire
2 months ago - Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 - GlobeNewsWire